KUALA LUMPUR: Based on the outcomes of the I-TECH study by the Institute for Clinical Research (ICR), Ivermectin cannot be recommended for inclusion in the current COVID-19 treatment guidelines as it does not reduce the risk of severe illness from COVID-19.
Director-General of Health, Tan Sri Dr Noor Hisham Abdullah in a statement today said this was because Ivermectin did not reduce the risk of severe COVID-19 disease.
"MOH (Ministry of Health) recommends that Ivermectin be used only in clinical studies with monitoring," he said.
According to him, the results of the I-TECH study are in line with the large-scale studies such as IVERCOR-COVID-19 from Argentina and TOGETHER from Brazil that do not support the routine use of Ivermectin in the clinical practice of COVID-19 treatment.
The I-TECH research team planned to submit the study data for publication in a peer-reviewed journal to provide additional information on the Ivermectin studies including meta-analysis, he said.
Dr Noor Hisham said the I-TECH study was conducted on 500 COVID-19 patients admitted to hospital in Stage two or three categories by evaluating the effectiveness of a five-day Ivermectin treatment (0.4mg/kg/day) with Ivermectin standard of care (IVM group) compared to just the standard of care (SOC group).
"The SOC treatment for the group undergoing it was based on the Health Ministry's guidelines for COVID-19 patients in 20 government hospitals and the COVID-19 Quarantine and Treatment Centre at the Malaysia Agro Exposition Park Serdang (MAEPS) 2.0.
"The clinical trial study was conducted by infectious disease physicians and clinicians who were actively involved in COVID-19 management in collaboration with ICR under the National Institute of Health.
"The I-TECH study was to see whether the administration of Ivermectin in the first week on patients experiencing symptoms of COVID-19 could prevent them from getting worse (Stage four or five) which was among patients aged 50 years and above and having at least one comorbidity," he said.
He added that the I-TECH lead researcher, Dr Steven Lim Chee Loon, infectious disease specialist from the Raja Permaisuri Bainun Hospital in Ipoh, revealed that no significant difference was found in terms of ICU admission, usage of breathing support equipment, recovery of symptoms, blood test parameter and chest X-ray scans among the two groups.
"The probability to fully recover from the symptoms on the fifth day among the two groups was almost similar, where there was no statistically significant difference recorded (p=0.77).
"Apart from that, the safety analysis reported a three-fold occurrence of side effects among the IVM group, compared with the SOC group, of which most of them were diarrhoea cases.
"It is hoped that the local study could provide enlightenment to medical practitioners in Malaysia and the public who have been asking about the efficacy of Ivermectin in the COVID-19 clinical treatment practice," he said.
He also reminded medical practitioners not to recommend the use of Ivermectin, including sharing advertisements or illegal sale of Ivermectin to treat COVID-19 until more solid scientific evidence is available.
-- BERNAMA
Bernama
Wed Nov 03 2021
Based on the outcomes of the I-TECH study by the Institute for Clinical Research (ICR), Ivermectin cannot be recommended for inclusion in the current COVID-19 treatment guidelines as it does not reduce the risk of severe illness from COVID-19.
Penjawat awam rugi lebih RM150,000 diperdaya 'phone scam'
Seorang penjawat awam mengalami kerugian RM150,600 selepas terperdaya dengan sindiket 'phone scam'atau penipuan melalui panggilan telefon,
Polis Israel lerai penunjuk perasaan anti-kerajaan
Polis Israel menolak dan menyembur penunjuk perasaan dengan meriam air semasa protes anti-kerajaan di Tel Aviv pada Sabtu.
Penunjuk perasaan menuntut tamatnya perang untuk membebaskan tebusan dan menuduh Perdana Menteri Israel Benjamin Netanyahu tidak mahu mencapai perjanjian gencatan senjata dengan Hamas, termasuk pembebasan tebusan.
Penunjuk perasaan menuntut tamatnya perang untuk membebaskan tebusan dan menuduh Perdana Menteri Israel Benjamin Netanyahu tidak mahu mencapai perjanjian gencatan senjata dengan Hamas, termasuk pembebasan tebusan.
Masalah disiplin remaja antara tiga cabaran utama dihadapi kaum ibu - Nancy
Masalah disiplin remaja merupakan antara tiga cabaran utama dihadapi kaum ibu ketika ini.
PH pertahan DUN Kuala Kubu Baharu, majoriti 3,869 undi
Pengarah Eksekutif Ilham Centre, Hisomuddin Bakar berkongsi pandangan mengenai keputusan Pilihan Raya Kecil (PRK) Dewan Undangan Negeri (DUN) Kuala Kubu Baharu yang menyaksikan PH berjaya mempertaahankan kerusi berkenaan.
Dituduh jadi 'badi' dalam keluarga, ibu tergamak buang anak OKU dalam lubuk buaya
Mangsa yang dikenal pasti sebagai Vinod disahkan mengalami masalah pendengaran dan pertuturan.
Hari Ibu: Raja Permaisuri Agong berangkat ke sambutan peringkat kebangsaan
Seri Paduka Baginda Raja Permaisuri Agong, Raja Zarith Sofiah berkenan berangkat ke majlis sambutan Hari Ibu Peringkat Kebangsaan 2024 Di Pusat Keluarga Lembaga Penduduk Dan Pembangunan Keluarga Negara (Lppkn) Di Ayer Keroh, Melaka.
JS-SEZ dijangka dibangunkan di Iskandar Malaysia dan Pengerang - Onn Hafiz
Zon Ekonomi Khas Johor-Singapura (JSSEZ) dijangka dibangunkan di kawasan Iskandar Malaysia dan Pengerang melibatkan keluasan 3,505 kilometer persegi.
KKM sasar sifar kes kusta menjelang 2030
Kementerian Kesihatan (KKM) menyasarkan sifar kes kusta tempatan baharu menjelang 2030, kata Menterinya Datuk Seri Dr Dzulkefly Ahmad.
MFL diminta pertingkat kawalan keselamatan di stadium, tempat penginapan
Persatuan Bolasepak Malaysia (FAM) meminta Liga Bola Sepak Malaysia (MFL) meningkatkan tahap keselamatan pemain ketika pergi dan pulang dari stadium.
Ballon d’Or berpotensi milik Vinicius - Carlo Ancelotti
Junior merakamkan persembahan menakjubkan untuk membantu Real Madrid memenangi trofi saingan LaLiga dan memburu Piala Liga Juara-juara Eropah keduanya.
Ivermectin tidak berkesan cegah gejala teruk COVID-19 - Kajian penyelidik Malaysia
Kumpulan penyelidik Malaysia dipetik sebagai berkata, penemuan mereka itu sekali gus tidak menyokong penggunaan Ivermectin untuk pesakit COVID-19.
KKM cadang laksana kajian klinikal guna Ivermectin ke atas kontak rapat COVID-19
Institut Penyelidikan Klinikal Kebangsaan (ICR) masih menunggu kelulusan dari Bahagian Regulatori Farmasi Negara (NPRA) untuk melaksanakan kajian klinikal ini.
Tidak kurangkan risiko COVID-19, KKM tidak syorkan Ivermectin - Dr Noor Hisham
Keputusan itu dikeluarkan susulan hasil dapatan kajian Ivermectin (I-Tech) ke atas 500 pesakit COVID-19 melibatkan kategori 2 atau 3.
Keputusan kajian Ivermectin akan dibentangkan minggu hadapan
Khairy berkata kajian tempatan berkaitan ubat tersebut sudah selesai dan keputusan sudah diperolehi.
Penjualan Ivermectin: Polis sedia bantu KKM - Mazlan
Polis sedia membantu jika pihak Kementerian Kesihatan (KKM) membuat aduan berhubung penjualan secara haram ubat Ivermectin sebagai penawar COVID-19.
Penggunaan Ivermectin hanya untuk tujuan ujian klinikal - MPS
KKM akan menjalankan ujian klinikal terhadap 500 pesakit, untuk menilai keberkesanan penggunaan Ivermectin.
Jual ubat Ivermectin: 'KKM, MCMC jangan lepas tangan' - Persatuan Farmasi Malaysia
Tindakan berani pihak yang cuba mengambil kesempatan itu adalah salah di bawah Akta Racun 1952, Akta Jualan Dadah 1952 dan Akta Ubat (Iklan dan Penjualan) 1956.
Penjual ubat Ivermectin berdepan tindakan
Amrahi menggesa agar kerajaan mengambil tindakan terhadap penjualan ubat ini sama ada secara dalam talian atau dibawa masuk dari luar negara.
Mesyuarat Khas Parlimen: Ahli Parlimen PH dikritik desak guna Ivermectin rawat COVID-19
Beberapa Ahli Parlimen pembangkang dikiritik pengamal perubatan dan netizen kerana mendesak Kementerian Kesihatan (KKM) meluluskan penggunaan Ivermectin untuk merawat pesakit COVID-19.
Penggunaan Ivermectin: Tunggu keputusan ujian klinikal KKM - Pakar kesihatan
sebarang keputusan akan dibuat berdasarkan evidence-based medicine, dan KKM dijangka mengeluarkan keputusan berhubung ujian klinikal Ivermectin pada September ini.